Cargando…
The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
Primary membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome in adults, due to a variety of autoantibodies, most frequently against phospholipase A2 receptor (PLA2R). In severe cases or when spontaneous remission is not achieved, immunosuppression is required. Cyclical therap...
Autores principales: | Alberici, Federico, Mescia, Federica, Scolari, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468754/ https://www.ncbi.nlm.nih.gov/pubmed/37669306 http://dx.doi.org/10.1093/ckj/sfad081 |
Ejemplares similares
-
Therapy of membranous nephropathy: quo vadis?
por: Glassock, Richard J
Publicado: (2023) -
Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
por: Zand, Ladan, et al.
Publicado: (2023) -
Congenital nephrotic syndrome: is early aggressive treatment needed? Yes
por: Hölttä, Tuula, et al.
Publicado: (2020) -
Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!
por: Rossignol, Patrick, et al.
Publicado: (2023) -
Dietary sodium and cardiovascular and renal disease risk factors: dark horse or phantom entry?
por: McCarron, David A.
Publicado: (2008)